Difference between revisions of "Money"
| Line 1: | Line 1: | ||
| + | == Funding overview == | ||
| + | Governments are the biggest players in the tobacco market. In the US, for example, various areas of government at the turn of the twenty-first century received around $40 billion annually from tobacco, against less than $9 billion received by the entire industry. It is governments that benefit from and control the tobacco trade far more than the tobacco industry, which has been virtually nationalized by taxation and the US Master Settlement Agreement (MSA) with the states. The MSA is a price-fixing scheme which makes manufacturers, in effect, surrogate tax collectors, even as direct government-collected taxes also continue to grow exponentially. The situation is similar worldwide, where total taxes on cigarettes typically outstrip the actual price of cigarettes, several times to one. | ||
| + | |||
| + | As the Big Tobacco industry, shrunken, regulated into submission, and gagged against protest, has declined, the Tobacco Control industry, supported by governments and the pharmaceutical industry which produces “smoking cessation” products, has become a financial colossus. The losers are the people. Their losses come in the form of suffering a divisive victimization campaign against smokers, wealth wasted on TC bureaucracy and junk science research, tarnishing of the good name of science, blocking of the development of effective reduced risk cigarettes, and oppression in the form of ever-encroaching restrictions on personal choice and individual freedom. All industries, in great part and essentially, are about money. The pharmaceutical and Tobacco Control industries are about very big money. A general illustration of forces in play is provided below. | ||
| + | |||
| + | |||
| + | [[File:TC_Money.jpg]] | ||
== Big Pharma funding of the anti-tobacco industry == | == Big Pharma funding of the anti-tobacco industry == | ||
Revision as of 13:41, 18 June 2012
Funding overview
Governments are the biggest players in the tobacco market. In the US, for example, various areas of government at the turn of the twenty-first century received around $40 billion annually from tobacco, against less than $9 billion received by the entire industry. It is governments that benefit from and control the tobacco trade far more than the tobacco industry, which has been virtually nationalized by taxation and the US Master Settlement Agreement (MSA) with the states. The MSA is a price-fixing scheme which makes manufacturers, in effect, surrogate tax collectors, even as direct government-collected taxes also continue to grow exponentially. The situation is similar worldwide, where total taxes on cigarettes typically outstrip the actual price of cigarettes, several times to one.
As the Big Tobacco industry, shrunken, regulated into submission, and gagged against protest, has declined, the Tobacco Control industry, supported by governments and the pharmaceutical industry which produces “smoking cessation” products, has become a financial colossus. The losers are the people. Their losses come in the form of suffering a divisive victimization campaign against smokers, wealth wasted on TC bureaucracy and junk science research, tarnishing of the good name of science, blocking of the development of effective reduced risk cigarettes, and oppression in the form of ever-encroaching restrictions on personal choice and individual freedom. All industries, in great part and essentially, are about money. The pharmaceutical and Tobacco Control industries are about very big money. A general illustration of forces in play is provided below.
Big Pharma funding of the anti-tobacco industry
Is Big Pharma funding smoking bans and other extreme anti-smoking campaigns? The money trail speaks for itself and this is only a very partial list :
WHO LAUNCHES PARTNERSHIP WITH THE PHARMACEUTICAL INDUSTRY TO HELP SMOKERS QUIT
Excerpt:
The strength of the Partnership Project lies in the fact that it has brought together three major pharmaceutical companies, Glaxo Wellcome, Novartis Consumer Health and Pharmacia & Upjohn, all manufacturers of treatment products for tobacco dependence, to support a common goal that will have a significant impact on public health. The Project provides a model which can provide a basis for future partnerships with the private sector in other important health areas.
Smoking bans: good public policy? Or simply a great pharmaceutical marketing plan?
Excerpt:
(...) upon some preliminary investigation it is clear that these NGO's are backed by $446,000,000.00 from the Robert Wood Johnson Foundation (RWJF) which has direct ties to the Johnson & Johnson Company, and J & J is the manufacturer of Nicoderm & Nicoderm CQ via its wholly owned subsidiary ALZA. Recently, the buyout of Pfizer Consumer Health(see page 4 or 61) means J & J profits even more from the passage of smoking bans thru additional sales of Nicotrol, Nicorette, Commit, (see pgs 32,33,56) and any other over the counter smoking cessation drugs once manufactured by Pfizer Consumer Health division. Global Health Partnerships
Alliance for Control of Tobacco Use (Brazil), Hellenic Thoracic Society (Greece), SAMBA (Sweden), and Umberto Veronesi Foundation (Italy)
• Developing Tobacco Control Capacity: Action on Smoking and Health (ASH) International/Framework Convention Alliance (FCA) (Brazil, Argentina, Venezuela, Mexico, Colombia, Chile and Costa Rica; Morocco, Algeria, Tunisia, Egypt, Saudi Arabia, Kuwait, UAE and Lebanon), and Mexican Council on Tobacco • Protecting Nonsmokers from Secondhand Smoke: American Cancer Society (Algeria and Tunisia) and Chinese Association on Tobacco Control
• Helping Smokers Quit: Comprehensive Cancer Center at Freiburg University Medical Center (Germany), Health Promotional Foundation (Poland), Heart and Stroke Foundation of Ontario (Canada), Hungarian Academy of Teaching Family Physicians, Japan Medical-Dental Association for Tobacco Control, Partnership for Prevention (U.S.), Philippine Business for Social Progress, QUIT UK/European Network of Quitlines (Central and Eastern Europe)
The following link leads to a letter from ASH, UK to GSK about how disgusted they are that Derek Bonham, Chairman of Imperial Tobacco sits on the board of GSK.
Links between ASH, UK and Glaxo Smith Klein (GSK)
Excerpts:
ASH has worked closely with both Glaxo and SmithKline Beecham staff and always welcomed the active collaboration. (...) We have worked with GSK under the auspices of the WHO-Europe Partnership Project on tobacco dependence and at various one-off opportunities. ASH was instrumental in securing greater government commitment to smoking cessation products in the NHS National Plan and we have helped with PR for both Zyban and Niquitin CQ. Our involvement with GSK staff has, I believe, been mutually beneficial, and we have gained from exposure to the company's arguments and insights (...)
This experience is replicated in many organisations, many countries and in business areas beyond the smoking cessation category. (...)
There are clear conflicts of interest - every time someone successfully uses a GSK smoking cessation product the market for tobacco declines. Every time a smoker switches to 'lights' as an alternative to quitting the market for smoking cessation is diminished.
Most of the measures that drive people to want to quit smoking and use GSK products are exactly those that are opposed by tobacco companies. Such measures include:
- Restrictions on smoking in public places and workplaces
- Marketing restrictions on tobacco companies
- Higher tobacco taxation
- Greater NHS involvement in smoking cessation
- Regulatory measures to be applied to tobacco products
(...)
ASH has a small shareholding in GSK and I will be attending with others to question you and the Chairman on this situation. (...) More than anything, I would like to resume normal and constructive relations with GlaxoSmithKline. (...)
Some examples of financial conflicts of interest between the anti-tobacco industry and Big Pharma:
